Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19

被引：35
|
作者：
Giovannoni, Gavin [1 ]
机构：
[1] Barts & London Queen Marys Sch Med & Dent, Blizard Inst, 4 Newark St, London E1 2AT, England
来源：
MULTIPLE SCLEROSIS AND RELATED DISORDERS | 2020年 / 41卷
关键词：
OCRELIZUMAB;
D O I：
10.1016/j.msard.2020.102135
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease
    Haeusler, Darius
    Haeusser-Kinzel, Silke
    Feldmann, Linda
    Torke, Sebastian
    Lepennetier, Gildas
    Bernard, Claude C. A.
    Zamvil, Scott S.
    Brueck, Wolfgang
    Lehmann-Horn, Klaus
    Weber, Martin S.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2018, 115 (39) : 9773 - 9778
  • [32] Learning multiple sclerosis immunopathogenesis from anti-CD20 therapy
    Heming, Michael
    Wiendl, Heinz
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2023, 120 (06)
  • [33] Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis
    Sellebjerg, Finn
    Blinkenberg, Morten
    Sorensen, Per Soelberg
    CNS DRUGS, 2020, 34 (03) : 269 - 280
  • [34] Knowledge domain and trend of disease-modifying therapies for multiple sclerosis: A study based on CiteSpace
    Zheng, Ting
    Jiang, Taotao
    Huang, Zilong
    Wang, Manxia
    HELIYON, 2024, 10 (05)
  • [35] Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: Pathogenesis, risk of infection, and disease management
    Alvarez, Enrique
    Longbrake, Erin E.
    Rammohan, Kottil W.
    Stankiewicz, James
    Hersh, Carrie M.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 79
  • [36] Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases
    Oksbjerg, N. R.
    Nielsen, S. D.
    Blinkenberg, M.
    Magyari, M.
    Sellebjerg, F.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 52
  • [37] Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies
    Gasperini, Claudio
    Haggiag, Shalom
    Ruggieri, Serena
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (10) : 1243 - 1253
  • [38] Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis
    Edward E. Neuberger
    Ibrahim M. Abbass
    Eddie Jones
    Natalie J. Engmann
    Neurology and Therapy, 2021, 10 : 183 - 196
  • [39] Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis
    Neuberger, Edward E.
    Abbass, Ibrahim M.
    Jones, Eddie
    Engmann, Natalie J.
    NEUROLOGY AND THERAPY, 2021, 10 (01) : 183 - 196
  • [40] The mechanism of action of anti-CD20 monoclonal antibodies used in the treatment of multiple sclerosis
    Mycko, Marcin P.
    AKTUALNOSCI NEUROLOGICZNE, 2023, 23 (03): : 72 - 78
12345